MedTrace Logo

Elucidate Vasodilatory Capacity From Histology-Defined Analysis of Coronary CT Angiography

NCT05524896 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 302

Last updated 2022-09-08

No results posted yet for this study

Summary

Coronary CT Angiography (CCTA) may be an ideal modality to fill gaps in understanding the extent and rate of progression coronary artery disease. The investigators have developed an image analysis software ElucidVivo that estimates relevant indices, including fractional flow reserve (FFR) . In this study, the investigators aim to assess the value of ElucidVivo-based plaque morphology characterization for predicting non-invasive FFR in patients with suspected coronary artery disease (CAD) who had undergone clinically indicated coronary CTA and invasive coronary angiography (ICA) for physical FFR measurement.

Conditions

  • Vascular Diseases

Interventions

DEVICE

ElucidVivo

Plaque morphology characterization for predicting non-invasive fractional flow reserve (FFR)

Sponsors & Collaborators

  • St. Francis Medical Center, New Jersey

    collaborator OTHER

  • The Christ Hospital

    collaborator OTHER

  • Medical University of South Carolina

    collaborator OTHER

  • Mie University

    collaborator OTHER

  • Elucid Bioimaging Inc.

    lead INDUSTRY

Principal Investigators

  • Andrew J Buckler · Elucid Bioimaging Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2021-05-31
Completion
2022-07-13
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05524896 on ClinicalTrials.gov